Infusion chairs
The newly expanded TRC facility includes 18 beds and four infusion chairs.

The focus of the Translational Research Center (TRC), unlike those facilities run by many contract research organizations, is the recruitment of patients, rather than normal/healthy volunteers, into early stage, proof-of-concept trials.

The value of early treatment of patients with a potential therapeutic is that it provides evidence for efficacy in the target treatment population.

It also allows measurements of key biochemical, genetic, and radiological parameters to be made in affected individuals.

With the expansion of its facility from five to 18 beds in late 2016, the TRC has substantially increased its capacity and is seeking new partnerships with the biopharma community.

We are now conducting a large number (>140) of active protocols, approximately 20% of which are industry-sponsored. We have also introduced a new partnership model with a single administrative docking point to streamline contract negotiations and IRB approvals to better meet the timelines typical of industry studies.

For smaller biotech companies with limited in-house clinical expertise, the TRC can bring disease experts from Mass General and beyond to build clinical trial protocols that ask and answer key questions in the evaluation of a novel therapeutic.

Located on the Mass General main campus, the TRC includes 18 beds and four infusion chairs. Each bed is standardized to meet the hospital requirements for any inpatient, including central monitoring.

There are two private rooms with air flow monitoring suitable for a wide range of studies involving gene therapy vectors or other agents where containment of biological materials is critical.

The staff includes expert research nurses, nurse practitioners, research nutritionists, laboratory technicians, and project managers. Both adult and pediatric study participants can be accommodated.

The laboratory and imaging technical capabilities of the hospital (e.g., genomics, specialized immunological assays, PET scanning) are available for studies where those modalities can illuminate key research questions.

The TRC can draw from a pool of 3 million patients cared for in the Mass General/Partners Healthcare System and match them with the right clinical investigator from the 2,500 physician scientists at Mass General, who are leading experts in their respective disciplines.

Back to Top